Ultragenyx Gets $203M in Second Priority Review Voucher This Month @checkrare
Ultragenyx Gets $203M in Second Priority Review Voucher This Month  @checkrare
Uploaded October 2026 | Updated November 2026, 4 days ago
On this episode, we discuss the FDA approval of Enspryng for TED, the new FDA Rare Disease Framework Initiative, Ultrangenyx’s second sold PRV this month, and using AI to reduce diagnostic delays.

Produced by CheckRare.

Explore additional CME activities, physician interviews, podcasts, and rare disease resources at CheckRare.com. Subscribe to the CheckRare Podcast Network for the latest rare disease education, expert interviews, and weekly news.

Part of the CheckRare Podcast Network: Trusted conversations, news, education, and expert insights across the rare disease community.
Ultragenyx Gets $203M in Second Priority Review Voucher This MonthPatient Perspective: Diagnosis and Treatment Journey With ROS1-Positive Non-Small Cell Lung CancerClinical Trials in Rare Endocrine Disorders | Rare Endocrine ExchangeTopline Results From the SANRECO Trial Testing Divesiran in Polycythemia VeraTETON-2 Findings in Treatment of Idiopathic Pulmonary Fibrosis #podcast #rarediseaseCongenital Adrenal Hyperplasia: Effect of Crenessity (Crinecerfont) on Bone Age AdvancementEfficacy of Infigratinib on AchondroplasiaMolecular Changes Associated With Teprotumumab Treatment in Thyroid Eye DiseaseInvestigating Results From the MAVORIC Trial in Patients With CTCLMiv-cel Shows Durable Results in Stiff Person Syndrome and Myasthenia GravisUCB Study Highlights the Burden of Ocular Myasthenia GravisGambling on Clinical Trials
CheckRare |

Ultragenyx Gets $203M in Second Priority Review Voucher This Month

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER